-
公开(公告)号：US20120046450A1
公开(公告)日：2012-02-23
申请号：US13190199
申请日：2011-07-25
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
公开(公告)号：US08008443B2
公开(公告)日：2011-08-30
申请号：US11912562
申请日：2006-04-25
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
公开(公告)号：US20110077383A1
公开(公告)日：2011-03-31
申请号：US12666331
申请日：2008-07-02
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , C07K16/2866 , C07K2317/21 , C07K2317/53 , C07K2317/56 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改进稳定性和/或改变Fc与一个或多个金属离子和/或一个或多个金属离子的结合 更多的Fc配体（例如FcγR）和/或调节效应子功能。 更具体地，本发明提供对金属离子介导的切割较不敏感和/或具有对一个或多个FcγR和/或C1q的修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 此外，Fc变体的修饰的铰链保持与野生型铰链相似的柔性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
公开(公告)号：US20050181479A1
公开(公告)日：2005-08-18
申请号：US11071304
申请日：2005-03-04
CPC分类号： C07K16/40 , C07H21/04 , C07K16/00 , C07K2317/55 , C07K2317/565
摘要： The present invention relates to recombinant polynucleotides, expression vectors and methods for the production of multimeric proteins. The vectors and methods are useful for the production of multimeric protein and are unique in that they utilize a minimal number of signal sequences. More specifically, the present invention provides recombinant polynucleotide molecules and expression vectors comprising a promoter region operably linked to a transcription unit. The transcription unit is characterized by at least two DNA sequences encoding distinct polypeptides wherein at least one but not all DNA sequences further encodes a signal sequence operably linked to the DNA sequence encoding a polypeptide. The invention further provides methods of producing a multimeric protein using the expression vectors of the present invention.
摘要翻译： 本发明涉及重组多核苷酸，表达载体和用于产生多聚体蛋白质的方法。 载体和方法可用于生产多聚体蛋白质，并且是唯一的，因为它们利用最少量的信号序列。 更具体地，本发明提供重组多核苷酸分子和包含可操作地连接到转录单位的启动子区的表达载体。 转录单元的特征在于编码不同多肽的至少两个DNA序列，其中至少一个但不是全部DNA序列进一步编码与编码多肽的DNA序列可操作地连接的信号序列。 本发明还提供使用本发明的表达载体产生多聚体蛋白质的方法。
-
公开(公告)号：US20090221803A1
公开(公告)日：2009-09-03
申请号：US11912562
申请日：2006-04-25
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如，FcγRs）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或Clq具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
公开(公告)号：US08697396B2
公开(公告)日：2014-04-15
申请号：US13190199
申请日：2011-07-25
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
7.发明授权Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease 有权人源化抗CD19抗体及其在治疗肿瘤，移植和自身免疫疾病中的应用公开(公告)号：US08323653B2
公开(公告)日：2012-12-04
申请号：US11852106
申请日：2007-09-07
申请人： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
发明人： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
摘要翻译： 本发明提供抗CD19小鼠单克隆抗体的嵌合和人源化形式。 本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人CD19抗原并且可介导ADCC，CDC和/或细胞凋亡以治疗B细胞疾病和病症的治疗性抗体的方法，例如但不 限于B细胞恶性肿瘤，用于治疗和预防自身免疫疾病，以及用于治疗和预防人类移植受体中移植物抗宿主病（GVHD），体液排斥和移植后淋巴增殖性疾病。
-
8.发明申请Humanized Anti-CD19 Antibodies And Their Use In Treatment Of Oncology, Transplantation And Autoimmune Disease 有权人源化抗CD19抗体及其在肿瘤，移植和自身免疫性疾病治疗中的应用公开(公告)号：US20080138336A1
公开(公告)日：2008-06-12
申请号：US11852106
申请日：2007-09-07
申请人： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
发明人： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , A61P37/00 , C12N5/06
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
摘要翻译： 本发明提供抗CD19小鼠单克隆抗体的嵌合和人源化形式。 本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人CD19抗原并且可介导ADCC，CDC和/或细胞凋亡以治疗B细胞疾病和病症的治疗性抗体的方法，例如但不 限于B细胞恶性肿瘤，用于治疗和预防自身免疫疾病，以及用于治疗和预防人类移植受体中移植物抗宿主病（GVHD），体液排斥和移植后淋巴增殖性疾病。
-
9.发明申请AFFINITY OPTIMIZED EPHA2 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开亲和力优化的EPHA2激动抗体及其使用方法公开(公告)号：US20090220527A1
公开(公告)日：2009-09-03
申请号：US12158651
申请日：2006-12-20
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/622 , C07K2317/92
摘要： The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
摘要翻译： 本发明涉及具有较高亲和力的抗体，其优先结合暴露于癌细胞而非非癌细胞的EphA2表位。 本发明还涉及设计用于治疗，管理或预防癌症，特别是转移性癌症的方法和组合物。 本发明还提供包含本发明的一种或多种EphA2抗体的药物组合物，其单独或与一种或多种其它可用于癌症治疗的试剂组合。
-
10.发明申请Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis 审中-公开通过定点诱变增加哺乳动物细胞中重组抗体的产生公开(公告)号：US20060019342A1
公开(公告)日：2006-01-26
申请号：US11165023
申请日：2005-06-24
CPC分类号： C07K16/2866 , C07K16/00 , C07K16/2848 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/92 , C12N2510/02
摘要： The present invention relates to a reliable, reproducible method for improving the producibility of an antibody. More specifically, this invention provides a method for modifying the heavy chain of an antibody to improve its producibility in eukaryotic cells. Additionally, the method of the invention may improve both antibody producibility and one or more antigen binding characteristics. The invention further provides modified antibodies which are better produced and which have either no change in their antigen binding characteristics or exhibit improved antigen binding characteristics.
摘要翻译： 本发明涉及提高抗体可生产性的可靠，可重现的方法。 更具体地，本发明提供了修饰抗体重链以改善其在真核细胞中的可生产性的方法。 此外，本发明的方法可以改善抗体可产生性和一种或多种抗原结合特征。 本发明还提供了更好地产生并且其抗原结合特征没有变化或表现出改善的抗原结合特征的修饰抗体。
-
-
-
-
-
-
-
-
-
搜索结果
100 条记录 (耗时 0.053 秒)